
Acquisition - February 24, 2021
Xbrane divests Primm Pharma
Xbrane Biopharma has entered into a non-binding term-sheet with NewFaDem for a divestment of Primm Pharma. Xbrane’s long term focus is to become a world leading biosimilar developer, and hence Primm Pharma falls outside its strategic scope, the company states in its press release. A total consideration of up to €14 million The non-binding terms […]